AbbVie: Apogee Deal and Cancer Success Fuel the Stock
Reading Time: 2 minutes
Phase 3 data on Epcoritamab show an impressive reduction in disease progression in cancer medicine by up to 60%. The strategic acquisition of Apogee Therapeutics for $10.9 billion ignites the next growth turbo in the immunology business. An upgraded annual forecast and the expansion of the biopharma pipeline are currently attracting massive institutional capital. The pharmaceutical giant AbbVie is experiencing massive trading volume, driven by a clinical breakthrough and a billion-dollar strategic acquisition. As one of the world's leading...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
